(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Conditions
Breast
Phase II
Volunteers
Health Professionals
What is the purpose of this trial?
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
- Trial withEastern Cooperative Oncology Group (ECOG)
- Start Date11/09/2021
- End Date02/28/2023
I'm interested in volunteering
If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alessia Donadio, MD
- Andrea Brennan
- Andrea Martelli
- Anna Fleischman
- Armand Russo, MD
- Ashita Talsania, MRCP, MBBS
- Benjamin Newton, MD
- Beverly Drucker, MD, PhD
- Brooke Chaves
- D. Barry Boyd, MD, MS
- Daniel P. Petrylak, MD
- David Witt, MD
- Elan Gorshein, DO, JD, MPH
- Elizabeth Cappiello
- Eric Winer, MD
- Francesca Montanari, MD
- Gloria Huang, MD, FACOG
- Ian Krop, MD, PhD
- Jade Vanacore
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jason Haldas, MD
- Javin Brita, PA
- Jeremy Kortmansky, MD
- Johanna LaSala, MD
- Jose Morales-Marin
- Justin Persico, MD
- Karishma Mehra, MBBS
- Katherine Harvey, MD, MPH
- Kathleen Fenn, MD
- Kathryn Daniels
- Kelsey Martin, MD
- Kerin Adelson, MD
- Kert Sabbath, MD, FACP
- Kristen Hoxie
- Lajos Pusztai, MD, DPhil
- M. Sung Lee, MD
- Madeline Santiago
- Mariya Rozenblit, MD
- Maryam Lustberg, MD, MPH
- Matthew Austin, MD
- Michael Cohenuram, MD
- Michael DiGiovanna, MD, PhD
- Michael Grant, MD
- Michelle Corso
- Navid Hafez, MD, MPH
- Neal Fischbach, MD
- Pawan Karanam, MD
- Robert Legare, MD
- Sara Anastasio, RN
- Sarah Carlson
- Sarah Elizabeth Schellhorn, MD
- Sharynn Hall, MD, PhD
- Stephanie Paine, APRN
- Stephen Lattanzi, MD
- Su Hsien Lim, MD
- Tara Sanft, MD
- Victor Chang, MD
- Vidya Brown
- Virginia Syombathy
- Wajih Kidwai, MD, FACP
- Xuanthao Thi Nguyen
- Zia Rahman, MD
- Last Updated12/22/2022
- Study HIC#2000030283